Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Contrary to prevailing media narratives, accusing China of a 'wet market' leak—a practice framed as culturally backward—is a more politically disparaging attack than a 'lab leak,' a risk common to all scientifically advanced nations. The discourse around this was politically incoherent.

Related Insights

The administration was influenced by bearish Wall Street analyses after China's zero-COVID policy and the "Peak China" narrative in the strategic community. This led them to believe China was economically weaker than it was, causing them to miscalculate China's ability and willingness to retaliate in a trade war.

The ability to distinguish an engineered virus from a natural one is a critical deterrent. Proving a pathogen was deliberately created narrows the list of suspects to a handful of state programs, enabling political and intelligence-led responses that would otherwise be impossible.

During a 2023 meeting with President Biden, Chinese officials sprayed a DNA-degrading substance on everything Xi Jinping touched. This was done out of fear that the US could capture his DNA to create a genetically optimized virus, illustrating deep-seated paranoia about biological warfare.

Leaders create simplified, emotionally resonant narratives for public consumption that mask the messy, complex, and often ugly truths behind their actions. The real "why" is rarely present in the official story.

Contrary to lingering Western perceptions, the idea that data from Chinese biotechs is poor or that the country doesn't produce real innovation is outdated and incorrect. China's life sciences sector is now increasingly sophisticated and innovative, fueled by significant government investment, making it a critical global player that cannot be underestimated.

The US biotech industry's fixation on the "China threat" is largely a reaction to losing its undisputed global leadership position. Having never faced such potent competition, the industry is unsettled. The fact that the competitor is China, a geopolitical rival, amplifies this underlying anxiety about being dethroned.

China actively tries to shape global media narratives to counter U.S. policy. For example, it seeds stories in the Western press about its tech breakthroughs to suggest U.S. semiconductor export controls are failing, even while its diplomats privately demand the controls be lifted—a sign they are working.

Anthropic's choice to label data collection by Chinese labs as a 'distillation attack' is a strategic branding move. This framing aligns with their public image focused on AI safety and geopolitical concerns, rather than just being a technical description of the activity.

Beyond revealing systemic unpreparedness, the COVID-19 pandemic's most dangerous long-term consequence was the fracturing of public trust in science, health officials, and politicians. This erosion of trust severely cripples the ability to respond to future, more lethal pandemics.

The narrative of China as an innovation 'threat' in biopharma may be a deliberate strategy to spur action in the U.S. By creating a sense of urgency and competition, reminiscent of the U.S.-Soviet superpower struggle, the industry may be attempting to mobilize investment and political will, even if the framing is seen as unfortunate.

The 'Wet Market' COVID Origin Story Was a Harsher Political Attack on China Than 'Lab Leak' | RiffOn